ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates that activate the immune system of cancer patients to recognize and eradicate tumors. Co.'s lead product candidate includes AM0010, a drug that is in Phase III randomized pivotal clinical trial for the treatment of pancreatic ductal adenocarcinoma and chemotherapy. Co. is also developing AM0010 with anti-PD-1 immune checkpoint inhibitor that has completed Phase I/Ib clinical trial for the treatment of non-small cell lung cancer, as well as that is in Phase I/Ib clinical trial for the treatment of renal cell carcinoma, and melanoma and other solid tumors. We show 3 historical shares outstanding datapoints in our ARMO shares outstanding history coverage, used to compute ARMO market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ARMO market cap history over the course of time is important for investors
interested in comparing ARMO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ARMO versus a peer is one thing; comparing
ARMO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ARMO can fluctuate over the course of history.
With this page we aim to empower investors researching ARMO by allowing them to research the ARMO market cap history. |
Free ARMO Email Alerts:
Video: The Importance of Market Cap
